PharmaCyte Biotech Inc (PMCB):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:PharmaCyte Biotech Inc (PMCB) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C8077
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:55
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
PharmaCyte Biotech Inc (PharmaCyte), formerly Nuvilex Inc, is a clinical stage biotechnology company that develops and commercializes treatments for cancer and diabetes. The company offers technology is used for the treatment of advanced and inoperable pancreatic cancer and diabetes. It develops cell-in-a-box cellulose-based live cell encapsulation technology. PharmaCyte’s treatment for pancreatic cancer consists of the combination of live cells encapsulated using Cell-in-a-Box technology together with low doses of the anticancer prodrug ifosfamide. It conducts research in the areas of live cell encapsulation technology, pancreatic cancer, diabetes, cannabinoids and cancer and breast cancer, among others. PharmaCyte is headquartered in Laguna Hills, California, the US.

PharmaCyte Biotech Inc (PMCB) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
PharmaCyte Biotech Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
PharmaCyte Biotech Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
PharmaCyte Biotech Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
PharmaCyte Biotech Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
PharmaCyte Biotech Inc, Medical Devices Deals, 2012 to YTD 2018 10
PharmaCyte Biotech Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
PharmaCyte Biotech Inc, Pharmaceuticals & Healthcare, Deal Details 12
Asset Purchase 12
Nuvilex Acquires Rights To Live-Cell Encapsulation Technology For Diabetes From SG Austria 12
Partnerships 13
PharmaCyte Biotech Partners with Translational Drug Development and Clinical Network Services 13
PharmaCyte Biotech Enters into Co-Development Agreement with University of Technology Sydney 14
Licensing Agreements 15
PharmaCyte Biotech Enters into Licensing Agreement with Austrianova Singapore for Cannabis Therapies 15
PharmaCyte Biotech Enters into Licensing Agreement with Austrianova Singapore 16
Nuvilex Enters into Licensing Agreement with University of Technology Sydney 17
Equity Offering 18
PharmaCyte Biotech to Raise up to USD25 Million in Public Offering of Shares 18
PharmaCyte Biotech Raises USD1 Million in Private Placement of shares 19
Nuvilex to Raise up to USD50 Million in Public Offering of Shares 20
Nuvilex Completes First Tranche Of Private Placement Of Shares For US$2 Million 21
Nuvilex Competes Private Placement Of Securities For US$1.5 Million 22
Acquisition 23
Nuvilex Acquires 14.5% Stake In SGAustria, Life Science Company 23
Nuvilex Acquires Bio Blue Bird For US$1.5 Million 24
PharmaCyte Biotech Inc – Key Competitors 25
PharmaCyte Biotech Inc – Key Employees 26
PharmaCyte Biotech Inc – Locations And Subsidiaries 27
Head Office 27
Other Locations & Subsidiaries 27
Recent Developments 28
Corporate Communications 28
Oct 10, 2017: PharmaCyte Biotech Appoints Dr. Raymond Tong to Board of Directors 28
Jul 26, 2017: PharmaCyte Biotech Appoints Dr. Linda S. Sher as Chief Medical Officer 29
Jul 10, 2017: PharmaCyte Biotech Appoints Dr. Michael M. Abecassis to Board of Directors 31
May 02, 2017: PharmaCyte Biotech Appoints Thomas Yuen to Board of Directors 32
Apr 03, 2017: PharmaCyte Biotech Appoints Dr. Mark Rabe Director of Cannabis Program Development 33
Legal and Regulatory 34
Nov 16, 2017: British Columbia Securities Commission Revokes Cease Trade Order on PharmaCyte Biotech Securities 34
Government and Public Interest 36
Feb 23, 2017: First Ever Cannabis-Based ETF to Include PharmaCyte Biotech, Abbott Laboratories, and GW Pharmaceuticals 36
Product News 37
Dec 05, 2017: PharmaCyte Biotech Announces Production of Master Cell Bank 37
Oct 17, 2017: PharmaCyte Biotech Research Identifies Enzyme Activity for Cannabinoid-Based Therapy to Fight Cancer 38
04/18/2017: PharmaCyte Biotech Discusses Future of Cannabis Research Program, Competitors and More with Program’s Director 39
04/10/2017: PharmaCyte Biotech’s Cannabis Research Program Sees Significant Progress in University of Northern Colorado Presentations 41
Feb 13, 2017: PharmaCyte Biotech Moves Closer to Filing IND with Naming of Comparator Arm for Upcoming Clinical Trial and Discusses Pivotal Trial Opportunity 43
01/24/2017: PharmaCyte Going Head to Head with Eli Lillys Pancreatic Cancer Drug in New Clinical Trial 45
Jan 10, 2018: PharmaCyte Announces Completion of Master Cell Bank 47
Product Approvals 48
Feb 13, 2017: PharmaCyte Biotech Moves Closer to Filing IND with Naming of Comparator Arm for Upcoming Clinical Trial and Discusses Pivotal Trial Opportunity 48
Jan 30, 2017: PharmaCyte Biotech Retains Facet Life Sciences to Guide Pancreatic Cancer Therapy Development Lifecycle with FDA 50
Jan 04, 2017: PharmaCyte Biotech Announces Pre-IND Meeting Date with FDA 51
Clinical Trials 52
Feb 21, 2017: PharmaCyte Biotech Discusses Patient Enrollment and TD2s Role in Upcoming Clinical Trial 52
Other Significant Developments 54
Feb 06, 2018: PharmaCyte Announces Completion of Preparatory Work and Commencement of Testing by Eurofins of Cells from Its Master Cell Bank 54
Appendix 55
Methodology 55
About GlobalData 55
Contact Us 55
Disclaimer 55

List of Tables
PharmaCyte Biotech Inc, Pharmaceuticals & Healthcare, Key Facts, 2018 2
PharmaCyte Biotech Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
PharmaCyte Biotech Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
PharmaCyte Biotech Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
PharmaCyte Biotech Inc, Deals By Therapy Area, 2012 to YTD 2018 9
PharmaCyte Biotech Inc, Medical Devices Deals, 2012 to YTD 2018 10
PharmaCyte Biotech Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Nuvilex Acquires Rights To Live-Cell Encapsulation Technology For Diabetes From SG Austria 12
PharmaCyte Biotech Partners with Translational Drug Development and Clinical Network Services 13
PharmaCyte Biotech Enters into Co-Development Agreement with University of Technology Sydney 14
PharmaCyte Biotech Enters into Licensing Agreement with Austrianova Singapore for Cannabis Therapies 15
PharmaCyte Biotech Enters into Licensing Agreement with Austrianova Singapore 16
Nuvilex Enters into Licensing Agreement with University of Technology Sydney 17
PharmaCyte Biotech to Raise up to USD25 Million in Public Offering of Shares 18
PharmaCyte Biotech Raises USD1 Million in Private Placement of shares 19
Nuvilex to Raise up to USD50 Million in Public Offering of Shares 20
Nuvilex Completes First Tranche Of Private Placement Of Shares For US$2 Million 21
Nuvilex Competes Private Placement Of Securities For US$1.5 Million 22
Nuvilex Acquires 14.5% Stake In SGAustria, Life Science Company 23
Nuvilex Acquires Bio Blue Bird For US$1.5 Million 24
PharmaCyte Biotech Inc, Key Competitors 25
PharmaCyte Biotech Inc, Key Employees 26
PharmaCyte Biotech Inc, Subsidiaries 27

List of Figures
PharmaCyte Biotech Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
PharmaCyte Biotech Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
PharmaCyte Biotech Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
PharmaCyte Biotech Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
PharmaCyte Biotech Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
PharmaCyte Biotech Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
PharmaCyte Biotech Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
PharmaCyte Biotech Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
PharmaCyte Biotech Inc, Medical Devices Deals, 2012 to YTD 2018 10

★海外企業調査レポート[PharmaCyte Biotech Inc (PMCB):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Thermo Fisher Scientific Inc (TMO):医療機器:M&Aディール及び事業提携情報
    Summary Thermo Fisher Scientific Inc (Thermo Fisher) is a provider of equipment, analytical instruments, reagents and consumables, software and services to tackle complex analytical challenges in research, diagnostics and clinical laboratories. It offers solutions for cellular analysis and biology, …
  • DecImmune Therapeutics Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary DecImmune Therapeutics Inc (DecImmune) is a pharmaceutical research company. The company develops a humanised antibody, which is used in preventing tissue damage and block inflammation caused from vascular injuries. It conducts research and development on N2, an innate IgM-mediated auto-immu …
  • Shanghai Fosun Pharmaceutical (Group) Co Ltd (600196):企業の財務・戦略的SWOT分析
    Summary Shanghai Fosun Pharmaceutical (Group) Co Ltd (Fosun Pharma), a subsidiary of Shanghai Fosun High Technology (Group) Co Ltd is a drug company that offers pharmaceutical products, medical diagnostic products and medical device products. The company’s pharmaceutical products include metabolism …
  • Odebrecht SA:電力:M&Aディール及び事業提携情報
    Summary Odebrecht S.A. (Odebrecht) is a diversified company. It carries out engineering and infrastructure construction services, development and operation of energy and infrastructure projects and real estate development services. The company executed various engineering and construction projects s …
  • Virtusa Corp (VRTU):企業の財務・戦略的SWOT分析
    Virtusa Corp (VRTU) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • Goldman Sachs Private Wealth Management:企業の戦略・SWOT・財務情報
    Goldman Sachs Private Wealth Management - Strategy, SWOT and Corporate Finance Report Summary Goldman Sachs Private Wealth Management - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT a …
  • Signet Jewelers Limited:戦略・SWOT・企業財務分析
    Signet Jewelers Limited - Strategy, SWOT and Corporate Finance Report Summary Signet Jewelers Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Tenaga Nasional Bhd (TENAGA):企業の財務・戦略的SWOT分析
    Tenaga Nasional Bhd (TENAGA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • Orascom Construction Ltd (OC):企業の財務・戦略的SWOT分析
    Summary Orascom Construction Ltd (Orascom Construction) is an engineering and construction contracting company which concentrates on large industrial, commercial and infrastructure projects. The company offers services, which include civil engineering works, buildings construction and industrial com …
  • Libbey Inc (LBY):企業の財務・戦略的SWOT分析
    Libbey Inc (LBY) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Trinity Health:製薬・医療:M&Aディール及び事業提携情報
    Summary Trinity Health (Trinity) formerly known as CHE Trinity Health, is a national Catholic health care organization that provides health care solutions in the US. It operates through a network of hospitals, health care services, and advocate partnerships at community, regional, and national level …
  • NV Bekaert SA:戦略・SWOT・企業財務分析
    NV Bekaert SA - Strategy, SWOT and Corporate Finance Report Summary NV Bekaert SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Suedzucker Ag
    Suedzucker Ag - Strategy, SWOT and Corporate Finance Report Summary Suedzucker Ag - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • DHX Media Ltd.:企業のM&A・事業提携・投資動向
    DHX Media Ltd. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's DHX Media Ltd. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestmen …
  • Federal Agricultural Mortgage Corp (AGM):企業の財務・戦略的SWOT分析
    Summary Federal Agricultural Mortgage Corp (Farmer Mac) is a mortgage service provider that offers loan services. The organization’s services include custom solutions, credit protection, USDA guaranteed loan purchase, loan purchase, credit solutions, lending opportunities, and wholesale financing se …
  • Konica Minolta Medical Imaging USA Inc:医療機器:M&Aディール及び事業提携情報
    Summary Konica Minolta Medical Imaging USA Inc (KMMI), a subsidiary of Konica Minolta Inc is a medical device company that manufactures and distributes digital and traditional imaging products. The company provides comprehensive imaging solutions including, digital radiography, ultrasound, healthcar …
  • JetBlue Airways Corp:企業の戦略・SWOT・財務分析
    JetBlue Airways Corp - Strategy, SWOT and Corporate Finance Report Summary JetBlue Airways Corp - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Mr.Sub:企業の戦略・SWOT・財務情報
    Mr.Sub - Strategy, SWOT and Corporate Finance Report Summary Mr.Sub - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, prov …
  • NTT DOCOMO Inc:企業の戦略・SWOT・財務分析
    NTT DOCOMO Inc - Strategy, SWOT and Corporate Finance Report Summary NTT DOCOMO Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • Paladin Energy Ltd (PDN):企業の財務・戦略的SWOT分析
    Paladin Energy Ltd (PDN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆